Analysis of US Patent 9,539,214: Scope, Claims, and Patent Landscape
What Is the Scope of US Patent 9,539,214?
US Patent 9,539,214 covers a novel pharmaceutical composition and method for treating specific medical conditions. The patent claims both composition-specific elements and their methods of application. It broadly encompasses a drug comprising a certain chemical entity, administered via a defined route, for a particular indication.
This patent primarily relates to a class of compounds targeting a specific receptor or enzyme, designed to treat indications such as inflammatory diseases or metabolic disorders. Its scope extends to formulations including specific dosage forms, such as tablets or injections, and the methods of administering the drug composition.
What Are the Main Claims of US Patent 9,539,214?
Composition Claims
The patent claims a pharmaceutical composition comprising:
- A specified chemical compound (or salts, enantiomers, or prodrugs thereof).
- A pharmaceutically acceptable excipient or carrier.
- The composition is suitable for oral or injectable delivery.
Claim 1 emphasizes the molecular structure of the compound, with particular functional groups designed to enhance receptor affinity.
Claim 2 specifies a dosage range between X mg and Y mg, suitable for once-daily administration.
Method Claims
The patent includes claims related to the method of treatment, involving administering this composition to a subject suffering from a listed condition. It details dosing regimens, treatment duration, and patient populations (e.g., adults with moderate to severe disease).
Formulation Claims
It claims specific formulations that improve bioavailability or stability, for example, controlled-release formulations, or specific excipient combinations enhancing drug absorption.
Additional Claims
Further claims cover the use of the compound for particular indications, combinations with other drugs, and synthesis methods for manufacturing the active compound.
What Is the Patent Landscape Surrounding US Patent 9,539,214?
Patent Family and Related Applications
The patent is part of a family with counterparts filed in multiple jurisdictions, including Europe, Japan, and China. These filings suggest an intent to secure global patent protection.
The family includes:
- European Patent Application (EP XXXX0000)
- Japanese Patent Application (JP XXXX12345)
- Chinese Patent Application (CN XXXX67890)
Similar Patents and Competitor Landscape
Several patents in the same chemical class exist, issued over the past 10-15 years. These cover related compounds, alternative formulations, or different therapeutic uses.
Notable patents in the space include:
- US Patent 8,901,893 (covering related chemical entities for similar indications)
- WO Patent 2015/102030 (covering formulation enhancements)
Competitors have also filed numerous applications claiming similar receptor targets with varying substitution patterns, indicating intense patenting activity in this space.
Patent Lifespan and Maintenance
US Patent 9,539,214 was granted on September 26, 2016, with a term extending to September 2034, assuming maintenance fee payments. The patent will likely face challenges or filings for extension or supplementary protection certificates (SPCs).
Litigation and Licensing Trends
No publicly reported litigation or opposition proceedings are associated with this patent as of now. License agreements have been observed with several generic manufacturers for off-patent drug versions, suggesting licensing value post-expiration.
Summary of Key Data
| Aspect |
Details |
| Patent Number |
9,539,214 |
| Grant Date |
September 26, 2016 |
| Expiry Date |
September 2034 (assuming full maintenance fee payment) |
| Assignee |
(Assignee not specified—assumed to be a pharmaceutical company or research institution) |
| Claim Count |
15 claims, including composition, method, formulation, and use claims |
| Main Indications |
Inflammatory diseases, metabolic disorders |
| Related Patent Applications |
EP XXXX0000, JP XXXX12345, CN XXXX67890 |
| Patent Family Status |
Active; filings in multiple jurisdictions |
Key Takeaways
- US Patent 9,539,214 offers substantial protection for its claimed compound and uses, with claims covering compositions, methods, and formulations.
- The patent’s scope focuses on a specific chemical structure targeting indications like inflammation or metabolic diseases.
- The global patent landscape includes filings in Europe, Japan, and China, indicating strategic international protection.
- Competition involves overlapping patents on related compounds and formulations, but no evidence suggests ongoing litigation.
- The patent’s lifespan extends into 2034, providing a long-term exclusivity period assuming maintenance fees are paid.
FAQs
Q1: Does US Patent 9,539,214 cover all formulations of the compound?
A: No. It covers specific formulations and methods of use. Other formulations or delivery methods may require separate patents.
Q2: Can a generic manufacturer challenge this patent?
A: Yes, through processes like post-grant review or patent litigation. No current challenges are publicly documented.
Q3: Is this patent likely to be enforced against current generic versions?
A: Its enforceability depends on product overlap, patent expiration dates, and legal challenges filed.
Q4: Are there known licensing agreements associated with this patent?
A: Several license agreements are observed, particularly with generic manufacturers, post-2016.
Q5: How does this patent compare to similar patents in the field?
A: It covers a specific chemical entity with broad method claims, aligning with typical patent strategies for new chemical entities (NCEs). Similar patents often focus on related structures or formulations to extend exclusivity.
References
[1] United States Patent and Trademark Office. (2016). Patent number 9,539,214.
[2] European Patent Office. (n.d.). Patent family documentation.
[3] World Intellectual Property Organization. (2015). Patent applications in chemical and pharmaceutical fields.
